Entrada Therapeutics experienced a significant drop in stock value, losing 55% after disappointing early data from its experimental Duchenne muscular dystrophy treatment, ENTR-601-44. While the Phase 1/2 study indicated positive safety and some efficacy—showing that patients could get off the floor more quickly—dystrophin production increased by only 2.36%, well below analyst expectations of over 10%.
The company will need to explore higher doses to compete with more advanced treatments, like Avidity Biosciences’ “del-zota” therapy, which has shown a 25% increase in dystrophin production and is on track for potential approval. Despite challenges, there are elements of interest in ENTR-601-44’s performance, especially related to time-to-rise data. Duchenne muscular dystrophy primarily affects children and severely impairs muscle function due to genetic mutations affecting dystrophin production.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biopharmadive.com/news/entrada-duchenne-data-stock-biotech-clinical-trial/819602/
